Brief: Orchard Therapeutics Completes Submission Of Biologics License Application For OTL-200 In MLD To U.S. FDA
03/08/2023 15:21
Aug 3 (Reuters) - Orchard Therapeutics PLC OT10y.F :
* ORCHARD THERAPEUTICS COMPLETES SUBMISSION OF BIOLOGICS
LICENSE
APPLICATION FOR OTL-200 IN MLD TO U.S. FDA
* ORCHARD THERAPEUTICS PLC - $34.0M OF ADDITIONAL CAPITAL
FROM
SECOND CLOSING OF STRATEGIC FINANCING EXTENDS RUNWAY TO MID-2025
Source text for Eikon: ID:nGNXby20YG
Further company coverage: OT10y.F
((Reuters.Brief@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln